This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30<a href="https://solaci.org/en/2015/06/24/corevalve-evolut-r-ce-good-results-at-6-months-of-the-new-corevalve-repositionable/" title="Read more" >...</a>
Article Up to 50% of acute myocardial infarctions are associated to mitral regurgitation of some degree and 10% of these cases present, at least, moderate regurgitation. Ischemic mitral regurgitation is associated to an increase of mortality and morbidity. For surgical patients with moderate regurgitation, the benefits mitral valve repair remain unclear. 301 patients were randomized<a href="https://solaci.org/en/2015/06/24/mitral-valve-repair-in-moderate-ischemic-mitral-regurgitation/" title="Read more" >...</a>
Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement. The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,<a href="https://solaci.org/en/2015/06/24/us-corevalve-cost-effectiveness-of-transcatheter-replacement-versus-surgical-replacement-in-high-risk-patients/" title="Read more" >...</a>
This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery. The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/corevalve-us-pivotal-trial-2-year-results-of-the-self-expanding-valve-on-inoperable-patients/" title="Read more" >...</a>
This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P <0.0001). By dividing patients by STS<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-5-year-results-of-a-balloon-expandable-valve-on-inoperable-patients/" title="Read more" >...</a>
The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the works performed neuroimaging new post, TAVR defects were observed in two-thirds of patients and this increases the risk of post clinical stroke. There is a missing data in the literature of<a href="https://solaci.org/en/2015/06/24/clean-tavi-transcatheter-aortic-valve-replacement-with-cerebral-protection/" title="Read more" >...</a>
Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at 2 years was 27.7% (31.5% SOURCE study). The incidence of stroke at 2 years was 7.7% and moderate to severe aortic regurgitation 7.3% and 0.2% respectively. There was a significant improvement in functional class and<a href="https://solaci.org/en/2015/06/24/source-xt-results-at-2-years-of-sapien-xt-valve/" title="Read more" >...</a>
Direct Flow Medical prosthesis is a nonmetallic, repositionable, recaptured valve (even after posts dilate), that does not require a pacemakers use during both implantation and post-dilatation. The aim of this study was to evaluate new valve results to one year in patients with symptomatic severe aortic stenosis with 19 and 26 mm ring, EuroScore of<a href="https://solaci.org/en/2015/06/24/discover-trial-results-at-one-year-of-the-new-nonmetallic-percutaneous-aortic-valve/" title="Read more" >...</a>
The incidence of permanent pacemaker implantation (PPM) is variable between the different series within 30 days of the aortic valve implantation with the CoreValve prosthesis. The aim of this study was to investigate the conduction abnormalities and PPM according to the Conduction Disorders Guide. This multicentre prospective study with a follow-up to 7 days, 30<a href="https://solaci.org/en/2015/06/24/advance-ii-low-incidence-of-permanent-pacemaker-for-self-expandable-valve/" title="Read more" >...</a>